Alkermes’ Vivitrol Patent Settlement Blocks Teva Copy Till 2027

Alkermes Plc settled a patent-infringement lawsuit over Teva Pharmaceutical Industries Ltd.’s proposed copy of the alcohol-dependence drug Vivitrol before a New Jersey federal judge could rule on their June bench trial.

Teva agreed that its generic naltrexone for extended-release injectable suspension would infringe the patent if it isn’t found invalid or unenforceable, according to Alkermes’ letter and proposed stipulated consent judgment and injunction filed Wednesday in the US District Court for the District of New Jersey.

Judge Madeline Cox Arleo also issued an order Wednesday administratively terminating the case for as long as 60 days while the parties finalize the ...